WO2004037183A3 - Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases - Google Patents
Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases Download PDFInfo
- Publication number
- WO2004037183A3 WO2004037183A3 PCT/US2003/033400 US0333400W WO2004037183A3 WO 2004037183 A3 WO2004037183 A3 WO 2004037183A3 US 0333400 W US0333400 W US 0333400W WO 2004037183 A3 WO2004037183 A3 WO 2004037183A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fibrosis
- disease
- pkg
- compound
- arteriosclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003286555A AU2003286555A1 (en) | 2002-10-22 | 2003-10-21 | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases |
US10/779,069 US8133903B2 (en) | 2003-10-21 | 2004-02-13 | Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
US13/372,094 US20120141454A1 (en) | 2003-10-21 | 2012-02-13 | Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases |
US14/215,444 US20140200219A1 (en) | 2002-10-22 | 2014-03-17 | Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases |
US15/277,550 US20170239257A1 (en) | 2002-10-22 | 2016-09-27 | Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases |
US15/832,918 US20180318307A1 (en) | 2003-10-21 | 2017-12-06 | Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42028102P | 2002-10-22 | 2002-10-22 | |
US60/420,281 | 2002-10-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004037183A2 WO2004037183A2 (en) | 2004-05-06 |
WO2004037183A3 true WO2004037183A3 (en) | 2004-08-05 |
Family
ID=32176545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/033400 WO2004037183A2 (en) | 2002-10-22 | 2003-10-21 | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003286555A1 (en) |
WO (1) | WO2004037183A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004038328A1 (en) * | 2004-08-06 | 2006-03-16 | Bayer Healthcare Ag | New uses of 2-phenyl-substituted imidazotriazinone derivatives |
CA2577442A1 (en) | 2004-08-17 | 2006-03-02 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
TWI339578B (en) | 2004-10-29 | 2011-04-01 | Mitsubishi Tanabe Pharma Corp | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions |
UA86528C2 (en) * | 2005-06-10 | 2009-04-27 | Донг-А Фармацевтікал.Ко., Лтд. | composition for prevention and treatment of liver diseases containing pyrazolopyrimidine derivative |
CA2704100C (en) * | 2007-10-26 | 2017-07-04 | Pacific Therapeutics Ltd. | Compositions and methods for treating fibroproliferative disorders |
RU2625726C2 (en) | 2011-07-20 | 2017-07-18 | Медиваунд Лтд. | Bromelain extract with proteolytic activity to treat connective tissue diseases |
WO2014100733A1 (en) | 2012-12-21 | 2014-06-26 | Mayo Foundation For Medical Education And Research | Methods and materials for treating calcific aortic valve stenosis |
JP2018505156A (en) * | 2015-01-06 | 2018-02-22 | インプリミス・ファーマシューティカルズ・インコーポレイテッドImprimis Pharmaceuticals, Inc. | Pharmaceutical formulation of xanthine or xanthine derivative |
EP3595623B1 (en) | 2017-03-14 | 2024-05-01 | Atir Holding S.A. | Topical formulation for the treatment of pigmented skin |
US11033549B2 (en) | 2017-03-14 | 2021-06-15 | Atir Holding S.A. | Use of heterocyclic compounds in the treatment of pigmented skin |
CN112773898A (en) * | 2019-11-11 | 2021-05-11 | 广州华真医药科技有限公司 | Application of phosphodiesterase 5 inhibitor in preparing anti-fibrosis disease medicine |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824669A (en) * | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
US5981563A (en) * | 1995-04-28 | 1999-11-09 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
US5990103A (en) * | 1994-08-25 | 1999-11-23 | Hoechst Aktiengesllschaft | Combination preparation for use in immunological diseases |
-
2003
- 2003-10-21 WO PCT/US2003/033400 patent/WO2004037183A2/en not_active Application Discontinuation
- 2003-10-21 AU AU2003286555A patent/AU2003286555A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5990103A (en) * | 1994-08-25 | 1999-11-23 | Hoechst Aktiengesllschaft | Combination preparation for use in immunological diseases |
US5981563A (en) * | 1995-04-28 | 1999-11-09 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
US5824669A (en) * | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
Also Published As
Publication number | Publication date |
---|---|
AU2003286555A1 (en) | 2004-05-13 |
WO2004037183A2 (en) | 2004-05-06 |
AU2003286555A8 (en) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004037183A3 (en) | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases | |
Stacy Smith et al. | Short incubation PDT versus 5-FU in treating actinic keratoses | |
IL159205A0 (en) | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | |
WO2005051229A3 (en) | Devices delivering therapeutic agents and methods regarding the same | |
Wang et al. | Treatment of skin cancer and pre-cancer using topical ALA-PDT—a single hospital experience | |
WO2002002090A3 (en) | Inhibitors of copper-containing amine oxidases | |
WO2002064163A3 (en) | Reduction or prevention of pdt related inflammation | |
DE60107065D1 (en) | TREATMENT OF CONGESTIVE HEART FAILURE BY PRE-TREATED AUTOLOGOUS BLOOD | |
BR0212252A (en) | Methods to Reduce Hypertension and Heart Failure in a Mammal | |
EA200001044A3 (en) | Nep inhibitors for the treatment of female sexual disfunction | |
Green et al. | Claviculectomy for subclavian venous repair: long-term functional results | |
WO2003009777A3 (en) | Delivery of therapeutic capable agents | |
Schanzer | Endovenous ablation plus microphlebectomy/sclerotherapy for the treatment of varicose veins: single or two-stage procedure? | |
Moore et al. | Minocycline-induced postsclerotherapy pigmentation successfully treated with a picosecond alexandrite laser | |
Russell et al. | Zimmer splintage: a simple effective treatment for keloids following ear-piercing | |
WO2001089517A3 (en) | Inhibition of cell proliferation and matrix synthesis by antioxidants and nad(p)h oxidase inhibitors | |
WO2001035997A3 (en) | Use of low-dose pdt to inhibit restenosis | |
WO1999040945A3 (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
Hansen et al. | Piercing of the glans penis | |
CA3168207A1 (en) | Cellular uptake | |
Purcell et al. | Intense pulsed light therapy in the management of hereditary benign telangiectasia | |
Takemaru et al. | Labial adhesions causing recurrent urinary-tract infections in an elderly woman | |
WO2003037308A3 (en) | Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion | |
Edris et al. | Vaginal tightening surgery: a new technique | |
RU2796245C1 (en) | Method of treatment of skin neoplasms by cryodestruction in animals, mainly in cats and dogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |